These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 32570252)

  • 1. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for inflammatory bowel diseases.
    Verstockt B; Ferrante M; Vermeire S; Van Assche G
    J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: emerging drug therapies in inflammatory bowel disease.
    Grossberg LB; Papamichael K; Cheifetz AS
    Aliment Pharmacol Ther; 2022 Apr; 55(7):789-804. PubMed ID: 35166398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
    Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
    Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.
    Vetter M; Neurath MF
    Therap Adv Gastroenterol; 2017 Oct; 10(10):773-790. PubMed ID: 29051788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins].
    Kim KO; Lee SH
    Korean J Gastroenterol; 2024 Aug; 84(2):43-50. PubMed ID: 39176460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
    Baker KF; Isaacs JD
    Ann Rheum Dis; 2018 Feb; 77(2):175-187. PubMed ID: 28765121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Therapeutics for IBD.
    Löwenberg M; D'Haens G
    Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Yarur A; Giles DA; Yeasmin S; Lundborg L; Sandborn WJ; Patel DR; Rivera-Nieves J
    Front Pharmacol; 2019; 10():212. PubMed ID: 30930775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators].
    Jun YK; Yoon H
    Korean J Gastroenterol; 2024 Aug; 84(2):51-64. PubMed ID: 39176461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and Emerging Treatments for Inflammatory Bowel Disease.
    Higashiyama M; Hokari R
    Digestion; 2023; 104(1):74-81. PubMed ID: 36366823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
    Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: novel oral-targeted therapies in inflammatory bowel disease.
    White JR; Phillips F; Monaghan T; Fateen W; Samuel S; Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1610-1622. PubMed ID: 29672874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
    Núñez P; Quera R; Yarur AJ
    Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.